In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.
The application of comprehensive genomic profiling (CGP) in patients with metastatic solid tumors aims to identify therapeutic options that were not otherwise evident with standard workup. However, CGP -- even when it analyzes patient samples against 500+ potential mutations — does not always identify an actionable target. In these cases, clinicians still need to develop a care plan based on best evidence and individual patient goals.
Our panel will discuss several of these cases in detail and recommend next steps.
The session will wrap up with a live Q&A in which attendees can discuss the cases with the Virtual Molecular Tumor Board panelists.
The Virtual Molecular Tumor Board Series is an interactive and educational online program intended to highlight the key role that molecular tumor boards play in implementing precision oncology.
The series will underscore the collaborative nature of genomic medicine by assembling a multidisciplinary panel of experts who will meet virtually for four one-hour sessions. In each session, the panel will review the genomic and clinical evidence for anonymized patients who have had their tumors sequenced as part of clinical management. The panel will discuss each case and recommend a course of treatment.
Precision Oncology News would like to thank Clariifi for assistance in planning and executing this educational webinar series.